| Advantage India • Cost of conducting Phase II/III trials in India is 40%-60% lower than USA and European countries • Diversified Gene Pool • Availability of a large and diverse patient pool • Subject selection process is fast. Time to FPFV from Regulatory Submission is 12-16 weeks • Good Infrastructure and Communication facilities • India has diseases of the tropical world and developed countries |
||
| Disease Surveillance in India * | ||
 |
||
India's medical infrastructure at a glance • 5,097 hospitals • 737,000 nurses • 870,161 hospital beds • 403 medical colleges • 503,900 doctors * Data Courtsey: CII Report |
||
